Coeptis Therapeutics (NASDAQ:ZSQR) Sees Large Volume Increase – Still a Buy?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) shares saw unusually-high trading volume on Wednesday . Approximately 214,714 shares changed hands during trading, an increase of 156% from the previous session’s volume of 84,030 shares.The stock last traded at $9.87 and had previously closed at $9.47.

Coeptis Therapeutics Price Performance

The company’s 50-day simple moving average is $12.00 and its 200-day simple moving average is $13.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.25 and a current ratio of 3.25. The company has a market capitalization of $473.68 million, a PE ratio of -3.65 and a beta of -0.09.

Coeptis Therapeutics (NASDAQ:ZSQR) last announced its earnings results on Thursday, May 14th. The company reported ($0.65) EPS for the quarter. The business had revenue of $0.11 million during the quarter. Coeptis Therapeutics had a negative net margin of 810.04% and a negative return on equity of 92.29%.

Hedge Funds Weigh In On Coeptis Therapeutics

Several institutional investors have recently bought and sold shares of ZSQR. Marshall Wace LLP acquired a new position in Coeptis Therapeutics in the 4th quarter valued at $259,000. Yorkville Advisors Global LP acquired a new position in shares of Coeptis Therapeutics during the third quarter worth about $140,000. State Street Corp increased its stake in shares of Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after acquiring an additional 6,962 shares during the period. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after acquiring an additional 4,721 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Coeptis Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after acquiring an additional 2,500 shares during the period. 13.88% of the stock is owned by institutional investors and hedge funds.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.